NCT03730051View on ClinicalTrials.gov

Dotarem vs Gadobutrol Contrast for Breast MRI

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

258

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Breast Diseases
Interventions
DRUG

Gadoterate meglumine

Participants randomized into this arm will receive gadoterate meglumine contrast for their scheduled breast MRI.

DRUG

Gadobutrol

Participants randomized into this arm will receive gadobutrol contrast for their scheduled breast MRI.

Trial Locations (1)

01655

UMass Medical School, Worcester

Sponsors

Collaborators (1)

Guerbet
All Listed Sponsors
collaborator

Guerbet

INDUSTRY

lead

University of Massachusetts, Worcester

OTHER

NCT03730051 - Dotarem vs Gadobutrol Contrast for Breast MRI | Biotech Hunter | Biotech Hunter